Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Small Cell Lung Carcinoma 1Neurofibromatosis 2 1Neoplasms 1Neoplasm Metastasis 1Meningioma 1DLBCL 1Carcinoma, Non-Small-Cell Lung 1Advanced Metastatic Breast Cancer 1

Interventions

Hydroxyurea 3Bevacizumab 3pembrolizumab 2Imatinib Mesylate 2Everolimus 2vistusertib 1vatalanib 1pasireotide 1fludarabine phosphate 1fludarabine 1arginyllysine 1antineoplaston AS 2-1 1antineoplaston A10 1aldesleukin 1Whole Body Imaging 1Verapamil 1Sunitinib 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Image-Guided 1Radiotherapy, Conformal 1Radiotherapy 1Radiosurgery 1Proton Therapy 1Nivolumab 1Modafinil 1Magnetic Resonance Spectroscopy 1Ipilimumab 1HDAC-42 1Fentanyl 1Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Meningioma × vistusertib × Clear all
NCT02831257 2022-06-13

AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas

Massachusetts General Hospital

Phase 2 Completed
18 enrolled 13 charts
CNS

Meningioma, Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡